Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

FDMT

4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FDMT
DateTimeSourceHeadlineSymbolCompany
07/23/20246:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
07/18/20248:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
07/17/20246:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
07/17/20245:00AMGlobeNewswire Inc.4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical ActivityNASDAQ:FDMT4D Molecular Therapeutics Inc
07/15/20246:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
07/12/20245:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
07/10/20245:17PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
06/24/20248:00AMGlobeNewswire Inc.4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic AtrophyNASDAQ:FDMT4D Molecular Therapeutics Inc
06/18/20248:00AMGlobeNewswire Inc.4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate WebcastNASDAQ:FDMT4D Molecular Therapeutics Inc
06/08/20244:30PMGlobeNewswire Inc.4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
06/07/20245:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
06/07/20245:04PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FDMT4D Molecular Therapeutics Inc
06/06/20247:30AMGlobeNewswire Inc.4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
06/04/20248:00AMGlobeNewswire Inc.4DMT Announces Presentations at Clinical Trials at the Summit 2024 MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
06/03/20248:00AMGlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
05/30/20248:00AMGlobeNewswire Inc.4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
05/24/20244:28PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
05/23/20247:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
05/23/20247:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
05/20/20248:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
05/09/20244:22PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
05/09/20244:05PMGlobeNewswire Inc.4DMT Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
05/07/20248:00AMGlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
05/01/20248:00AMGlobeNewswire Inc.4DMT Announces Presentations at ARVO 2024 Annual MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
03/28/20248:00AMGlobeNewswire Inc.4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisNASDAQ:FDMT4D Molecular Therapeutics Inc
03/04/20248:00AMGlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
02/29/20246:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
02/29/20245:15PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FDMT4D Molecular Therapeutics Inc
02/29/20244:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
02/29/20244:05PMGlobeNewswire Inc.4DMT Reports Full Year 2023 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FDMT